Keytruda for anpalstic thyroid caner – Iyer, P.C., Dadu, R., Gule-Monroe, M. et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. j. immunotherapy cancer 6, 68 (2018).
A retrospective study from Iyer et al It suggested that pembrolizumab could be used as a safe and effective salvage therapy to be added to kinase inhibitor therapy at the time of progression. However, there are no prospective studies of this approach and the Iyer paper concludes that this combination should be prospectively explored in clinical trials. A trial exploring combination immunotherapy and targeted therapy is currently open and enrolling (NCT03181100).
Iyer, P.C., Dadu, R., Gule-Monroe, M. et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. j. immunotherapy cancer 6, 68 (2018).
Dierks C, et al. Abstract 1824P. Presented at: European Society for Medical Oncology Congress; Oct. 19-23, 2018; Munich.
NCCN Thyroid Carcinoma ANAP-A 2020